Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 5Glioblastoma 2Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia 1Gliosarcoma 1Glioma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 28Radiosurgery 19Radiotherapy 17Bevacizumab 12Magnetic Resonance Spectroscopy 9Radiation 6Erlotinib Hydrochloride 6Carboplatin 6Topotecan 5Nivolumab 5Mental Status and Dementia Tests 5Irinotecan 5Capecitabine 5pembrolizumab 4dabrafenib 4Trastuzumab 4Sunitinib 4Pemetrexed 4Ipilimumab 4Filgrastim 4Cyclophosphamide 4Aminolevulinic Acid 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4cabozantinib 3Vorinostat 3TPI-287 3Specimen Handling 3Radiotherapy, Intensity-Modulated 3Methylphenidate 3Lomustine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Brain Neoplasms × Isotretinoin × Clear all
NCT01103375 2018-08-01

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

Wake Forest University Health Sciences

Phase 1 Terminated
5 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡